FAAH and MAGL inhibitors: Therapeutic opportunities from regulating endocannabinoid levels

Current Opinion in Investigational Drugs

Volumn 11, Issue 1, 2010, Pages 51-62

  Petrosino, Stefania ^a   Di Marzo, Vincenzo ^a  

^a CNR   (Italy)

Author keywords

2 Arachidonoyl glycerol; Anandamide; Arachidonoyl ethanolamide; Cannabinoid; Endocannabinoid; FAAH; Fatty acid amide hydrolase; MAGL; Monoacylglycerol lipase

Indexed keywords

4 [3 PHENYL (1,2,4)THIADIAZOL 5 YL]PIPERAZINE 1 CARBOXYLIC ACID PHENYLAMIDE; 7 PHENYL 1 [5 (2 PYRIDINYL) 2 OXAZOLYL] 1 HEPTANONE; ALPHA KH 7; APHA KH 7; ARACHIDONOYL SEROTONIN; BMS 1; CANNABINOID RECEPTOR; CARBAMIC ACID DERIVATIVE; CAY 10401; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; ESTERASE INHIBITOR; FATTY ACID AMIDASE INHIBITOR; JNJ 1661010; JZL 184; LY 2183240; MONOACYLGLYCEROL LIPASE INHIBITOR; OCTHILINONE; OMDM 119; OMDM 122; OMDM 132; OMDM 169; PF 04457845; PF 3845; PF 622; PF 750; SA 47; SA 72; SSR 411298; UNCLASSIFIED DRUG; UNINDEXED DRUG; URB 602; VER 24052;

ANXIETY DISORDER; CANCER CELL; CELL MIGRATION; CELL PROLIFERATION; CHRONIC PAIN; CLINICAL TRIAL; COLITIS; COMPETITIVE INHIBITION; DEGENERATIVE DISEASE; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENTERITIS; ENZYME REGULATION; ENZYME STRUCTURE; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; MAJOR DEPRESSION; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PAIN; POSTTRAUMATIC STRESS DISORDER; REGULATORY MECHANISM; REVIEW; SKIN DISEASE; THYROID TUMOR; TISSUE INJURY; TREATMENT OUTCOME; VOMITING;

AMIDOHYDROLASES; ANIMALS; ENDOCANNABINOIDS; ENZYME INHIBITORS; HUMANS; MONOACYLGLYCEROL LIPASES; PSYCHOTROPIC DRUGS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 74549185125     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 346(6284):561-564.
2. Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365(6441):61-65.
3. Di Marzo V, Fontana A: Anandamide, an endogenous cannabinomimetic eicosanoid: 'Killing two birds with one stone'. Prostaglandins Leukot Essent Fatty Acids (1995) 53(1):1-11.
4. Petrosino S, Ligresti A, Di Marzo V: Endocannabinoid chemical biology: A tool for the development of novel therapies. Curr Opin Chem Biol (2009) 13(3):309-320.
5. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 258(5090):1946-1949.
6. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG et al: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol (1995) 50(1):83-90.
7. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K: 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun (1995) 215(1):89-97.
8. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB: Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature (1996) 384(6604):83-87.
9. Karlsson M, Contreras JA, Hellman U, Tornqvist H, Holm C: cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. J Biol Chem (1997) 272(43):27218-27223.
10. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D: Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA (2002) 99(16):10819-10824.
11. Ligresti A, Petrosino S, Di Marzo V: From endocannabinoid profiling to 'endocannabinoid therapeutics'. Curr Opin Chem Biol (2009) 13(3):321-331.
12. Bracey MH, Hanson MA, Masuda KR, Stevens RC, Cravatt BF: Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science (2002) 298(5599):1793-1796.
13. McKinney MK, Cravatt BF: Structure and function of fatty acid amide hydrolase. Annu Rev Biochem (2005) 74:411-432.
14. Patricelli MP, Lovato MA, Cravatt BF: Chemical and mutagenic investigations of fatty acid amide hydrolase: Evidence for a family of serine hydrolases with distinct catalytic properties. Biochemistry (1999) 38(31):9804-9812.
15. Seierstad M, Breitenbucher JG: Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J Med Chem (2008) 51(23):7327-7343.
16. Chebrou H, Bigey F, Arnaud A, Galzy P: Study of the amidase signature group. Biochim Biophys Acta (1996) 1298(2):285-293.
17. Alexander JP, Cravatt BF: Mechanism of carbamate inactivation of FAAH: Implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem Biol (2005) 12(11):1179-1187.
18. Deutsch DG, Omeir R, Arreaza G, Salehani D, Prestwich GD, Huang Z, Howlett A: Methyl arachidonyl fluorophosphonate: A potent irreversible inhibitor of anandamide amidase. Biochem Pharmacol (1997) 53(3):255-260.
19. Bisogno T, Melck D, De Petrocellis L, Bobrov MYu, Gretskaya NM, Bezuglov VV, Sitachitta N, Gerwick WH, Di Marzo V: Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun (1998) 248(3):515-522.
20. Mor M, Rivara S, Lodola A, Plazzi PV, Tarzia G, Duranti A, Tontini A, Piersanti G, Kathuria S, Piomelli D: Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: Synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem (2004) 47(21):4998-5008.
21. Lodola A, Mor M, Hermann JC, Tarzia G, Piomelli D, Mulholland AJ: QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation. Chem Commun (Camb) (2005) (35):4399-4401.
22. Basso E, Duranti A, Mor M, Piomelli D, Tontini A, Tarzia G, Traldi P: Tandem mass spectrometric data-FAAH inhibitory activity relationships of some carbamic acid O-aryl esters. J Mass Spectrom (2004) 39(12):1450-1455.
23. Zhang D, Saraf A, Kolasa T, Bhatia P, Zheng GZ, Patel M, Lannoye GS, Richardson P, Stewart A, Rogers JC, Brioni JD, Surowy CS: Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as offtargets. Neuropharmacology (2007) 52(4):1095-1105.
24. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, Giustino A et al: Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med (2003) 9(1):76-81.
25. Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, Compton TR, Dasse O, Monaghan EP, Parrott JA, Putman D: Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev (2006) 12(1):21-38.
26. Sit SY, Conway C, Bertekap R, Xie K, Bourin C, Burris K, Deng H: Novel inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett (2007) 17(12):3287-3291.
27. Ortar G, Cascio MG, Moriello AS, Camalli M, Morera E, Nalli M, Di Marzo V: Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: A critical revisitation. Eur J Med Chem (2008) 43(1):62-72.
28. Moore SA, Nomikos GG, Dickason-Chesterfield AK, Schober DA, Schaus JM, Ying BP, Xu YC, Phebus L, Simmons RM, Li D, Iyengar S et al: Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proc Natl Acad Sci USA (2005) 102(49):17852-17857.
29. Alexander JP, Cravatt BF: The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. J Am Chem Soc (2006) 128(30):9699-9704.
30. Maione S, Morera E, Marabese I, Ligresti A, Luongo L, Ortar G, Di Marzo V: Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: Cannabinoid and noncannabinoid receptor-mediated mechanisms. Br J Pharmacol (2008) 155(5):775-782.
31. Boger DL, Miyauchi H, Du W, Hardouin C, Fecik RA, Cheng H, Hwang I, Hedrick MP, Leung D, Acevedo O, Guimarães CR et al: Discovery of a potent, selective, and efficacious class of reversible α-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J Med Chem (2005) 48(6): 1849-1856.
32. Leung D, Hardouin C, Boger DL, Cravatt BF: Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nat Biotechnol (2003) 21(6):687-691.
33. Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL, Cravatt BF: Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: Evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther (2004) 311(2):441-448.
34. Romero FA, Du W, Hwang I, Rayl TJ, Kimball FS, Leung D, Hoover HS, Apodaca RL, Breitenbucher JG, Cravatt BF, Boger DL: Potent and selective α-ketoheterocycle-based inhibitors of the anandamide and oleamide catabolizing enzyme, fatty acid amide hydrolase. J Med Chem (2007) 50(5):1058-1068.
35. Hardouin C, Kelso MJ, Romero FA, Rayl TJ, Leung D, Hwang I, Cravatt BF, Boger DL: Structure-activity relationships of α-ketooxazole inhibitors of fatty acid amide hydrolase. J Med Chem (2007) 50(14):3359-3368.
36. Kimball FS, Romero FA, Ezzili C, Garfunkle J, Rayl TJ, Hochstatter DG, Hwang I, Boger DL: Optimization of α-ketooxazole inhibitors of fatty acid amide hydrolase. J Med Chem (2008) 51(4):937-947.
37. Garfunkle J, Ezzili C, Rayl TJ, Hochstatter DG, Hwang I, Boger DL: Optimization of the central heterocycle of α-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem (2008) 51(15):4392-4403.
38. Minkkilä A, Saario SM, Käsnänen H, Leppänen J, Poso A, Nevalainen T: Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem (2008) 51(22):7057-7060.
39. Wang X, Sarris K, Kage K, Zhang D, Brown SP, Kolasa T, Surowy C, El Kouhen OF, Muchmore SW, Brioni JD, Stewart AO: Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors. J Med Chem (2009) 52(1):170-180.
40. Ahn K, Johnson DS, Fitzgerald LR, Liimatta M, Arendse A, Stevenson T, Lund ET, Nugent RA, Nomanbhoy TK, Alexander JP, Cravatt BF: Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry (2007) 46(45):13019-13030.
41. Johnson DS, Ahn K, Kesten S, Lazerwith SE, Song Y, Morris M, Fay L, Gregory T, Stiff C, Dunbar JB Jr, Liimatta M et al: Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH). Bioorg Med Chem Lett (2009) 19(10):2865-2869.
42. Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, Weerapana E, Sadagopan N, Liimatta M, Smith SE, Lazerwith S et al: Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol (2009) 16(4):411-420.
43. Keith JM, Apodaca R, Xiao W, Seierstad M, Pattabiraman K, Wu J, Webb M, Karbarz MJ, Brown S, Wilson S, Scott B et al: Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett (2008) 18(17):4838-4843.
44. Karbarz MJ, Luo L, Chang L, Tham CS, Palmer JA, Wilson SJ, Wennerholm ML, Brown SM, Scott BP, Apodaca RL, Keith J et al: Biochemical and biological properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase. Anesth Analg (2009) 108(1):316-329.
45. Hart T, Macias AT, Benwell K, Brooks T, D'Alessandro J, Dokurno P, Francis G, Gibbons B, Haymes T, Kennett G, Lightowler S et al: Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas. Bioorg Med Chem Lett (2009) 19(15):4241-4244.
46. Maione S, Bisogno T, de Novellis V, Palazzo E, Cristino L, Valenti M, Petrosino S, Guglielmotti V, Rossi F, Di Marzo V: Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther (2006) 316(3):969-982.
47. Palmer JA, Higuera ES, Chang L, Chaplan SR: Fatty acid amide hydrolase inhibition enhances the anti-allodynic actions of endocannabinoids in a model of acute pain adapted for the mouse. Neuroscience (2008) 154(4):1554-1561.
48. Desroches J, Guindon J, Lambert C, Beaulieu P: Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Br J Pharmacol (2008) 155(6):913-924.
49. Di Marzo V, Maccarrone M: FAAH and anandamide: Is 2-AG really the odd one out? Trends Pharmacol Sci (2008) 29(5):229-233.
50. Blankman JL, Simon GM, Cravatt BF: A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol (2007) 14(12):1347-1356.
51. Saario SM, Salo OM, Nevalainen T, Poso A, Laitinen JT, Järvinen T, Niemi R: Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Chem Biol (2005) 12(6):649-656.
52. Zvonok N, Williams J, Johnston M, Pandarinathan L, Janero DR, Li J, Krishnan SC, Makriyannis A: Full mass spectrometric characterization of human monoacylglycerol lipase generated by large-scale expression and single-step purification. J Proteome Res (2008) 7(5):2158-2164.
53. King AR, Lodola A, Carmi C, Fu J, Mor M, Piomelli D: A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors. Br J Pharmacol (2009) 157(6):974-983.
54. Goparaju SK, Ueda N, Taniguchi K, Yamamoto S: Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochem Pharmacol (1999) 57(4):417-423.
55. Saario SM, Savinainen JR, Laitinen JT, Järvinen T, Niemi R: Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Biochem Pharmacol (2004) 67(7):1381-1387.
56. King AR, Duranti A, Tontini A, Rivara S, Rosengarth A, Clapper JR, Astarita G, Geaga JA, Luecke H, Mor M, Tarzia G et al: URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. Chem Biol (2007) 14(12):1357-1365.
57. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, Krey JF, Walker JM, Holmes PV, Crystal JD, Duranti A et al: An endocannabinoid mechanism for stress-induced analgesia. Nature (2005) 435(7045):1108-1112.
58. Ortar G, Bisogno T, Ligresti A, Morera E, Nalli M, Di Marzo V: Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem (2008) 51(21):6970-6979.
59. Bisogno T, Ortar G, Petrosino S, Morera E, Palazzo E, Nalli M, Maione S, Di Marzo: Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo. Biochim Biophys Acta (2009) 1791(1):53-60.
60. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, Pavón FJ, Serrano AM, Selley DE, Parsons LH, Lichtman AH et al: Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol (2009) 5(1):37-44.
61. Di Marzo V, Petrocellis LD: Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med (2006) 57:553-574.
62. Ashton JC, Wright JL, McPartland JM, Tyndall JD: Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. Curr Med Chem (2008) 15(14): 1428-1443.
63. Maione S, De Petrocellis L, de Novellis V, Moriello AS, Petrosino S, Palazzo E, Rossi FS, Woodward DF, Di Marzo V: Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol (2007) 150(6):766-781.
64. Ortar G, Cascio MG, De Petrocellis L, Morera E, Rossi F, Schiano-Moriello A, Nalli M, de Novellis V, Woodward DF, Maione S, Di Marzo V: New N-arachidonoylserotonin analogues with potential 'dual' mechanism of action against pain. J Med Chem (2007) 50(26):6554-6569.
65. de Novellis V, Palazzo E, Rossi F, De Petrocellis L, Petrosino S, Guida F, Luongo L, Migliozzi A, Cristino L, Marabese I, Starowicz K et al: The analgesic effect of N-arachidonoylserotonin, a FAAH inhibitor and TRPV1 receptor antagonist, associated with changes in rostral ventromedial medulla and locus coeruleus cell activity in rats. Neuropharmacology (2008) 55(7):1105-1113.
66. Chang L, Luo L, Palmer JA, Sutton S, Wilson SJ, Barbier AJ, Breitenbucher JG, Chaplan SR, Webb M: Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol (2006) 148(1):102-113.
67. Russo R, Loverme J, La Rana G, Compton TR, Parrott J, Duranti A, Tontini A, Mor M, Tarzia G, Calignano A, Piomelli D: The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther (2007) 322(1):236-242.
68. Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, Vaughan CW: Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol (2006) 147(3):281-288.
69. Micale V, Cristino L, Tamburella A, Petrosino S, Leggio GM, Drago F, Di Marzo V: Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology (2009) 34(3):593-606.
70. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Cassano T, Morgese MG, Debonnel G, Duranti A, Tontini A et al: Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA (2005) 102(51):18620-18625.
71. Darmani NA, McClanahan BA, Trinh C, Petrosino S, Valenti M, Di Marzo V: Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. Neuropharmacology (2005) 49(4):502-513.
72. Sharkey KA, Cristino L, Oland LD, Van Sickle MD, Starowicz K, Pittman QJ, Guglielmotti V, Davison JS, Di Marzo V: Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. Eur J Neurosci (2007) 25(9):2773-2782.
73. Parker LA, Limebeer CL, Rock EM, Litt DL, Kwiatkowska M, Piomelli D: The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine-induced vomiting in the Suncus murinus (house musk shrew). Physiol Behav (2009) 97(1):121-124.
74. D'Argenio G, Valenti M, Scaglione G, Cosenza V, Sorrentini I, Di Marzo V: Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J (2006) 20(3):568-570.
75. Storr M, Emmerdinger D, Diegelmann J, Yüce B, Pfennig S, Ochsenkühn T, Göke B, Lohse P, Brand S: The role of fatty acid hydrolase gene variants in inflammatory bowel disease. Aliment Pharmacol Ther (2009) 29(5):542-551.
76. Ligresti A, Bisogno T, Matias I, De Petrocellis L, Cascio MG, Cosenza V, D'argenio G, Scaglione G, Bifulco M, Sorrentini I, Di Marzo V: Possible endocannabinoid control of colorectal cancer growth. Gastroenterology (2003) 125(3):677-687.
77. Bifulco M, Laezza C, Valenti M, Ligresti A, Portella G, Di Marzo V: A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J (2004) 18(13):1606-1608.
78. Izzo AA, Aviello G, Petrosino S, Orlando P, Marsicano G, Lutz B, Borrelli F, Capasso R, Nigam S, Capasso F, Di Marzo V et al: Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J Mol Med (2008) 86(1):89-98.
79. Endsley MP, Thill R, Choudhry I, Williams CL, Kajdacsy-Balla A, Campbell WB, Nithipatikom K: Expression and function of fatty acid amide hydrolase in prostate cancer. Int J Cancer (2008) 123(6):1318-1326.
80. Gubellini P, Picconi B, Bari M, Battista N, Calabresi P, Centonze D, Bernardi G, Finazzi-Agrò A, Maccarrone M: Experimental parkinsonism alters endocannabinoid degradation: Implications for striatal glutamatergic transmission. J Neurosci (2002) 22(16):6900-6907.
81. Bilsland LG, Dick JR, Pryce G, Petrosino S, Di Marzo V, Baker D, Greensmith L: Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J (2006) 20(7):1003-1005.
82. Morgese MG, Cassano T, Cuomo V, Giuffrida A: Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: Role of CB1 and TRPV1 receptors. Exp Neurol (2007) 208(1):110-119.
83. Webb M, Luo L, Ma JY, Tham CS: Genetic deletion of fatty acid amide hydrolase results in improved long-term outcome in chronic autoimmune encephalitis. Neurosci Lett (2008) 439(1):106-110.
84. Clement AB, Hawkins EG, Lichtman AH, Cravatt BF: Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J Neurosci (2003) 23(9):3916-3923.
85. Karanian DA, Brown QB, Makriyannis A, Kosten TA, Bahr BA: Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity. J Neurosci (2005) 25(34):7813-7820.
86. Schlosburg JE, Boger DL, Cravatt BF, Lichtman AH: Endocannabinoid modulation of scratching response in an acute allergenic model: A new prospective neural therapeutic target for pruritus. J Pharmacol Exp Ther (2009) 329(1):314-323.
87. Bátkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J, Offertáler L, Mackie K, Rudd MA, Bukoski RD, Kunos G: Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation (2004) 110(14):1996-2002.
88. Sarzani R, Bordicchia M, Salvi F, Cola G, Franchi E, Battistoni I, Mancinelli L, Giovagnoli A, Dessì-Fulgheri P, Rappelli A: A human fatty acid amide hydrolase (FAAH) functional gene variant is associated with lower blood pressure in young males. Am J Hypertens (2008) 21(8):960-963.
89. Comelli F, Giagnoni G, Bettoni I, Colleoni M, Costa B: The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation. Br J Pharmacol (2007) 152(5):787-794.
90. Kinsey SG, Long JZ, O'Neal ST, Abdullah RA, Poklis JL, Boger DL, Cravatt BF, Lichtman AH: Blockade of endocannabinoiddegrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther (2009) 330(3):902-910.
91. Nomura DK, Hudak CS, Ward AM, Burston JJ, Issa RS, Fisher KJ, Abood ME, Wiley JL, Lichtman AH, Casida JE: Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett (2008) 18(22):5875-5878.
92. Solinas M, Panlilio LV, Tanda G, Makriyannis A, Matthews SA, Goldberg SR: Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology (2005) 30(11):2046-2057.
93. Justinova Z, Munzar P, Panlilio LV, Yasar S, Redhi GH, Tanda G, Goldberg SR: Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB1-receptor antagonist rimonabant. Neuropsychopharmacology (2008) 33(12):2870-2877.
94. Sagar DR, Kendall DA, Chapman V: Inhibition of fatty acid amide hydrolase produces PPAR-α-mediated analgesia in a rat model of inflammatory pain. Br J Pharmacol (2008) 155(8):1297-1306.
95. Guindon J, LoVerme J, De Léan A, Piomelli D, Beaulieu P: Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: A role for endogenous fatty-acid ethanolamides? Eur J Pharmacol (2006) 550(1-3):68-77.
96. Naidu PS, Booker L, Cravatt BF, Lichtman AH: Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. J Pharmacol Exp Ther (2009) 329(1):48-56.
97. Fowler CJ, Naidu PS, Lichtman A, Onnis V: The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1. Br J Pharmacol (2009) 156(3):412-419.
98. Suplita RL 2nd, Farthing JN, Gutierrez T, Hohmann AG: Inhibition of fatty-acid amide hydrolase enhances cannabinoid stressinduced analgesia: Sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla. Neuropharmacology (2005) 49(8):1201-1209.
99. Llorente R, Llorente-Berzal A, Petrosino S, Marco EM, Guaza C, Prada C, López-Gallardo M, Di Marzo V, Viveros MP: Genderdependent cellular and biochemical effects of maternal deprivation on the hippocampus of neonatal rats: A possible role for the endocannabinoid system. Dev Neurobiol (2008) 68(11):1334-13347.
100. López-Gallardo M, Llorente R, Llorente-Berzal A, Marco EM, Prada C, Di Marzo V, Viveros MP: Neuronal and glial alterations in the cerebellar cortex of maternally deprived rats: Gender differences and modulatory effects of two inhibitors of endocannabinoid inactivation. Dev Neurobiol (2008) 68(12): 1429-1440.
101. Varvel SA, Cravatt BF, Engram AE, Lichtman AH: Fatty acid amide hydrolase (-/-) mice exhibit an increased sensitivity to the disruptive effects of anandamide or oleamide in a working memory water maze task. J Pharmacol Exp Ther (2006) 317(1): 251-257.
102. Varvel SA, Wise LE, Niyuhire F, Cravatt BF, Lichtman AH: Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Neuropsychopharmacology (2007) 32(5):1032-1041.
103. Jhaveri MD, Richardson D, Robinson I, Garle MJ, Patel A, Sun Y, Sagar DR, Bennett AJ, Alexander SP, Kendall DA, Barrett DA et al: Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-a in a model of inflammatory pain. Neuropharmacology (2008) 55(1):85-93.
104. Jhaveri MD, Richardson D, Kendall DA, Barrett DA, Chapman V: Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci (2006) 26(51): 13318-13327.
105. Hasanein P, Shahidi S, Komaki A, Mirazi N: Effects of URB597 as an inhibitor of fatty acid amide hydrolase on modulation of nociception in a rat model of cholestasis. Eur J Pharmacol (2008) 591(1-3):132-135.
106. Richardson D, Pearson RG, Kurian N, Latif ML, Garle MJ, Barrett DA, Kendall DA, Scammell BE, Reeve AJ, Chapman V: Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther (2008) 10(2):R43.
107. Naidu PS, Varvel SA, Ahn K, Cravatt BF, Martin BR, Lichtman AH: Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) (2007) 192(1):61-70.
108. Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D: Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry (2007) 62(10): 1103-1110.
109. Patel S, Hillard CJ: Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: Further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther (2006) 318(1):304-311.
110. Moreira FA, Kaiser N, Monory K, Lutz B: Reduced anxietylike behaviour induced by genetic and pharmacological inhibition of the endocannabinoid- degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology (2008) 54(1):141-150.
111. Scherma M, Medalie J, Fratta W, Vadivel SK, Makriyannis A, Piomelli D, Mikics E, Haller J, Yasar S, Tanda G, Goldberg SR: The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology (2008) 54(1):129-140.
112. Lisboa SF, Resstel LB, Aguiar DC, Guimarães FS: Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test. Eur J Pharmacol (2008) 593(1-3):73-78.
113. Cross-Mellor SK, Ossenkopp KP, Piomelli D, Parker LA: Effects of the FAAH inhibitor, URB597, and anandamide on lithiuminduced taste reactivity responses: A measure of nausea in the rat. Psychopharmacology (Berl) (2007) 190(2):135-143.
114. Rock EM, Limebeer CL, Mechoulam R, Piomelli D, Parker LA: The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology (Berl) (2008) 196(3):389-395.
115. Boger D, Sato H, Lerner AE, Hedrick MP, Fecik RA, Miyauchi H, Wilkie GD, Austin BJ, Patricelli MP, Cravatt BF. Exceptionally potent inhibitors of fatty acid amide hydrolase: The enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci USA (2000) 97(10):5044-5049.
116. Endsley MP, Thill R, Choudhry I, Williams CL, Kajdacsy-Balla A, Campbell WB, Nithipatikom K: Expression and function of fatty acid amide hydrolase in prostate cancer. Int J Cancer (2008)123(6):1318-1326.
117. Abouabdellah A, Burnier P, Hoornaert C, Jeunesse J, Puech F: Derivates of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of some in therapeutics. US-20060089344 (2006).
118. Abouabdellah A, Bas M, Dargazanli G, Hoornaert C, Li AT, Medaisko F: Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics. US-20050182130 (2005).
119. Discovery Partners International Inc [Infinity Pharmaceuticals Inc] (Adams J, Behnke M, Castro A, Evans C, Grenier L, Grogan M, Liu T, Snyder D, Tibbitts T): Inhibitors of fatty acid amide hydrolase. WO-2008063300 (2008).